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Methods 
For this study we used pre-existing plasma and muscle tissue obtained during a previously 
published study in which reduced PGC1α-signaling associated with loss of mitochondrial content 
was shown in vastus lateralis tissue obtained from 29 patients with clinically stable mild-to-moderate 
COPD versus 15 healthy controls.[1]  Patients were recruited from the outpatient clinic of the 
Maastricht University Medical Center (MUMC+, Maastricht, the Netherlands) and via 
advertisements in local newspapers. Patients were excluded if they were on long-term oxygen 
therapy, used oral prednisolone, or had an acute exacerbation of symptoms with hospital admission 
in the previous 8 wk and rehabilitation in the previous 6 months. Patients with a known comorbidity 
(e.g. diabetes, recent cardiovascular event, inflammatory bowel disease, obstructive sleep apnea, 
thyroid disease, and cancer) that could potentially interfere with study outcome parameters were 
carefully excluded. Healthy controls were recruited via advertising in local newspapers. The absence 
of these diseases in the healthy subjects was verified through history-taking by a physician and 
pulmonary function tests to verify the absence of airflow limitation.  Written, informed consent was 
obtained from all subjects and the ethical review board of the MUMC approved the study (08-2-059). 
The trial was registered at http://www.trialregister.nl as NTR1402. 
Muscle Biopsy 
Biopsies of the quadriceps muscle (vastus lateralis) from the dominant leg were obtained using a 
needle biopsy technique.[2] Tissue was snap-frozen in liquid nitrogen and stored at -80°C for gene 
and protein expression analyses. 
RNA Extraction and RT-qPCR Analysis 
Muscle tissue (10–30 mg) was homogenized in Denaturation Solution (ToTALLY RNA™ Kit; 
Ambion Ltd., Foster City, CA, USA) using a Polytron PT 1600 E (Kinematica AG, Littau/Luzern, 
Germany) and RNA extracted according to the supplier’s protocol, followed by genomic DNA 
removal and clean-up with the RNeasy Mini Kit with RNase-free DNase (Qiagen, Venlo, the 
Netherlands). After elution, RNA concentration was determined using a spectrophotometer 
(NanoDrop ND-1000, Isogen Lifescience, IJsselstein, the Netherlands) and integrity verified for a 
selection of samples by gel electrophoresis and on a Bioanalyzer (Agilent Technologies, Amstelveen, 
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the Netherlands). 400ng RNA was reverse transcribed to cDNA with anchored oligo(dT) primers 
according to the supplier’s protocol (Transcriptor First Strand cDNA Synthesis kit, Roche 
Diagnostics, Woerden, the Netherlands). RT-qPCR primers (table S1) were designed based on 
Ensembl transcript sequences and ordered from Sigma Genosys (Zwijndrecht, the Netherlands). The 
distance of the PCR primers to the 3’ termini was within the limit of the RT kit. The distance to the 3’ 
termini of the KAT1-4 primers was comparable. qPCR reactions contained Sensimix SYBR & ROX 
(Bioline, Waddinxveen, the Netherlands) and primer mix and were run in a 384 well white opaque 
plate on a LightCycler 480 system (Roche, Almere, the Netherlands). Melting curves were analysed 
to verify specificity of the amplification, and relative quantity of the targets was assessed by 
LinRegPCR software (v2014.8.1), which corrects for any potential differences in PCR efficiency for 
each target. GeNorm (Primerdesign, Southampton, USA) correction  was used to normalize 
expression of the target genes (housekeeping genes listed in e-Table 1).[3] Specific sample 
measurements were excluded when individual PCR efficiency was deviating from average PCR 
efficiency. 
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Table 1. Primer sequences. 
 Gene Name Forward Primer Reverse Primer ENSEMBL ID 
Targets    
PGC1a PPARgamma coactivator 1 beta GACCAGTGCTACCTGAGAGAGACTT GCTCGGCTCGGATTTCCT ENSG00000109819 
PPARa 
Peroxisome Proliferator Activated Receptor 
alpha  
CAGAACAAGGAGGCGGAGGTC AGGTCCAAGTTTGCGAAGC ENSG00000186951 
PPARg 
Peroxisome Proliferator Activated Receptor 
gamma  
CGGGCCCTGGCAAAAC AAGATCGCCCTCGCCTTT ENSG00000132170 
ERRa Estrogen related receptor alpha GCGGCTGGAGCGAGAGGAG CTCGGCATCTTCGATGTGCAC ENSG00000173153 
KAT1 Kynurenine aminotransferase 1 CCTGACTTGCCTGGAGCTGT GACAGGGATGGCCACCAA ENSG00000171097 
KAT2 Aminoadipate aminotransferase  TTCAGCTTCTCCAGAACAGATGG GCCACCATGCCCAACCTAGT ENSG00000109576 
KAT3 Kynurenine aminotransferase 3 CCATCCCCGTTTCAGCATT GCAGCATCCAGTGTGCTGTCT ENSG00000137944 
KAT4 Glutamic-oxaloacetic transaminase 2 GCAACACATCACCGACCAAA ATGCGGCCATCTTTTGTCAT ENSG00000125166 
Housekeepers    
B2m beta-2-microglobulin CTGTGCTCGCGCTACTCTCTCTT 
TGAGTAAACCTGAATCTTTGGAGTACG
C 
ENSG00000166710 
Ppia Cyclophilin CATCTGCACTGCCAAGACTGA TTCATGCCTTCTTTCACTTTGC ENSG00000196262 
Rpl13A Ribosomal protein 13A CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTCAA ENSG00000142541 
Rplp0 Large ribosomal protein TCTACAACCCTGAAGTGCTTGATATC GCAGACAGACACTGGCAACATT ENSG00000089157 
ALAS1 5-Aminolevulinate synthase CTGCAAAGATCTGACCCCTC CCTCATCCACGAAGGTGATT ENSG00000023330 
ACTB Beta Actin AAGCCACCCCACTTCTCTCTAA AATGCTATCACCTCCCCTGTGT ENSG00000075624 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase GCACCACCAACTGCTTAGCA TGGCAGTGATGGCATGGA ENSG00000111640 
GUSB Beta-glucuronidase CTCATTTGGAATTTTGCCGATT CCGAGTGAAGATCCCCTTTTTA ENSG00000169919 
HMBS Hydroxymethyl-bilane synthase GGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC ENSG00000256269 
HPRT1 Hypoxanthine phosphoribosyl-transferase 1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT ENSG00000165704 
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UBC Ubiquitin C ATTTGGGTCGCAGTTCTTG TGCCTTGACATTCTCGATGGT ENSG00000150991 
YWHA
Z 
Tyrosine 3-monooxygenase/ tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT ENSG00000164924 
 
Western Blotting  
Muscle tissue (10–20 mg) was crushed in liquid nitrogen and homogenized in 400μl IP lysis buffer (50mM Tris, 150mM NaCl, 10% glycerol, 0.5% Nonidet 
P40, 1mM EDTA, 1mM Na3VO4, 5mM NaF, 10mM β-glycerophosphate, 1mM Na4O7P2, 1mM dithiothreitol, 10μg/ml leupeptin, 1% aprotenin, 1mM PMSF, 
pH 7.4) with a Polytron PT 1600 E (Kinematica). After homogenization, samples were incubated for 15 minutes on a rotating wheel at 4°C and spun for 30 
minutes at maximum speed (20817×g) in a centrifuge cooled to 4°C. Supernatant was aliquoted, snap-frozen and stored without sample buﬀer at −80°C until 
analysis. 
Protein concentration in lysates was determined using the bicinchoninic acid assay (Pierce, Thermo Fisher Scientific, Breda, the Netherlands). For western 
blot analysis, aliquots were supplemented with 4× sample buffer (250mM Tris-HCl pH6.8, 8% (w/v) sodium dodecyl sulfate, 40% (v/v) glycerol, 0.4M 
dithiothreitol, 0.02% (w/v) bromophenol blue) and kept on ice. Per sample, 10 μg boiled protein was separated on gel (4-12% Bis-Tris XT gel, Criterion, Bio-
Rad) with XT MOPS running buffer (Bio-Rad). Proteins were transferred to a 0.45μm nitrocellulose membrane (Biorad, Veenendaal, the Netherlands) in 
transfer buffer (25mM Tris, 192mM glycine, 20% (v/v) methanol) by electrophoresis. After transfer, membranes were blocked from nonspecific protein binding 
with blocking solution, which contains 3% (w/v) non-fat dry milk (Campina, Eindhoven, the Netherlands) in Tris-buffered saline with Tween20 (TBST; 25mM 
Tris, 137mM NaCl, 2.7mM KCl, 0.05% (v/v) Tween20, pH 7.4), for one hour at room temperature, followed by incubation in primary antibody solution 
overnight at 4°C (rabbit anti-KAT1 (12156-1-AP; ProteinTech), anti-KAT2 (13031-1-AP; ProteinTech), anti-KAT3 (HPA026538; Atlas Antibodies), and anti-
KAT4 (ARP43518_T100; AVIVA Systems Biology) diluted 1:1000 in 1% BSA in TBST. Membranes were incubated in secondary antibody solution (peroxidase-
labeled horse anti-rabbit IgG (PI-1000, Vector Laboratories, Burlingame, CA, USA) diluted 1:10000 in blocking solution) for one hour at room temperature 
before incubation with enhanced chemiluminescence substrate (Pierce SuperSignal West PICO Chemiluminescent Substrate; Thermo Fisher Scientific). 
Protein bands were detected using a LAS-3000 Luminescent Image Analyzer (Fujifilm, Tokyo, Japan). PonceauS staining was used to control and correct for 
protein loading (in figure 1D the 300-20 kD range was cropped and downscaled vertically).  
Blood Analyses 
Kynurenine (KYN) and kynurenic acid (KYNA) were determined as previously described by Clarke et al.[4] Briefly, EDTA plasma samples were spiked 
with internal standard (3-Nitro-l-tyrosine) prior to being deproteinised by the addition of 20 μl of 4 M perchloric acid to 200 μl of sample. Samples were 
centrifuged at 21,000g on a Hettich Mikro 22R centrifuge (AGB, Dublin, Ireland) for 20 min at 4 °C and 100 μl of supernatant transferred to a HPLC vial for 
analysis on the HPLC system (UV and FLD detection). All samples were injected onto a reversed phase Luna 3 μm C18 (2) 150 × 2 mm column (Phenomenex), 
which was protected by KrudKatcher disposable pre-column filters (Phenomenex) and SecurityGuard cartridges (Phenomenex). The mobile phase consisted 
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of 50 mM acetic acid and 100 mM zinc acetate with 3% (v/v) acetonitrile and was filtered through Millipore 0.45-μm HV Durapore membrane filters (AGB) 
and vacuum degassed prior to use. Compounds were eluted isocratically over a 30-min runtime at a flow rate of 0.3 ml/min after a 20-μl injection. The column 
was maintained at a temperature of 30 °C, and samples/standards were kept at 8 °C in the cooled autoinjector prior to injection. The fluorescent detector was 
set at an excitation wavelength of 254 nm and an emission wavelength of 404 nm. The UV detector was set to 330 nm and kynurenines were identified by 
their characteristic retention times as determined by standard injections which were run at regular intervals during the sample analysis. Analyte:Internal 
standard peak height ratios were measured and compared with standard injections, and results were expressed as nanogram per milliliter of plasma.  
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